首页 > 最新文献

Lancet Respiratory Medicine最新文献

英文 中文
Incorrect interpretation of the role of COVID-19 vaccination boosters in saving lives 错误解读COVID-19疫苗接种促进剂在拯救生命方面的作用
IF 76.2 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2024-12-12 DOI: 10.1016/s2213-2600(24)00334-5
Tijl De Bie
No Abstract
没有抽象的
{"title":"Incorrect interpretation of the role of COVID-19 vaccination boosters in saving lives","authors":"Tijl De Bie","doi":"10.1016/s2213-2600(24)00334-5","DOIUrl":"https://doi.org/10.1016/s2213-2600(24)00334-5","url":null,"abstract":"No Abstract","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"35 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142815921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Caring for our interlocutors on the threshold of life and death 关心我们在生死边缘的对话者
IF 76.2 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2024-12-10 DOI: 10.1016/s2213-2600(24)00414-4
Magdalena Zegarra Chiappori
No Abstract
没有抽象的
{"title":"Caring for our interlocutors on the threshold of life and death","authors":"Magdalena Zegarra Chiappori","doi":"10.1016/s2213-2600(24)00414-4","DOIUrl":"https://doi.org/10.1016/s2213-2600(24)00414-4","url":null,"abstract":"No Abstract","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"39 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142804601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How Glasgow's 1957 tuberculosis screening programme could help countries today 格拉斯哥1957年的肺结核筛查项目对今天的国家有何帮助
IF 76.2 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2024-12-10 DOI: 10.1016/s2213-2600(24)00406-5
Peter Ranscombe
No Abstract
没有抽象的
{"title":"How Glasgow's 1957 tuberculosis screening programme could help countries today","authors":"Peter Ranscombe","doi":"10.1016/s2213-2600(24)00406-5","DOIUrl":"https://doi.org/10.1016/s2213-2600(24)00406-5","url":null,"abstract":"No Abstract","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"38 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142804600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating tezepelumab for COPD: a missed target or unmet potential? 评估tezepelumab治疗COPD:错过目标还是未实现的潜力?
IF 76.2 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2024-12-06 DOI: 10.1016/s2213-2600(24)00381-3
Mario Cazzola, Paola Rogliani, Maria Gabriella Matera
No Abstract
没有抽象的
{"title":"Evaluating tezepelumab for COPD: a missed target or unmet potential?","authors":"Mario Cazzola, Paola Rogliani, Maria Gabriella Matera","doi":"10.1016/s2213-2600(24)00381-3","DOIUrl":"https://doi.org/10.1016/s2213-2600(24)00381-3","url":null,"abstract":"No Abstract","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"199 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142788568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial tezepelumab与安慰剂在成人中度至极重度慢性阻塞性肺疾病(COURSE)中的疗效和安全性:一项随机、安慰剂对照的2a期试验
IF 76.2 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2024-12-06 DOI: 10.1016/s2213-2600(24)00324-2
Dave Singh, Christopher E Brightling, Klaus F Rabe, MeiLan K Han, Stephanie A Christenson, M Bradley Drummond, Alberto Papi, Ian D Pavord, Nestor A Molfino, Gun Almqvist, Ales Kotalik, Åsa Hellqvist, Monika Gołąbek, Navreet S Sindhwani, Sandhia S Ponnarambil
<h3>Background</h3>Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, which has shown increased expression in patients with chronic obstructive pulmonary disease (COPD) compared with healthy individuals. We aimed to assess the efficacy and safety of tezepelumab in patients with moderate to very severe COPD despite receiving triple inhaled therapy.<h3>Methods</h3>COURSE was a double-blind, randomised, placebo-controlled, phase 2a trial across 90 sites in ten countries in Asia, Europe, and North America. Eligible participants were aged 40–80 years, had moderate to very severe airflow limitation, were receiving triple inhaled maintenance therapy, and had at least two moderate to severe COPD exacerbations in the 12 months before enrolment. Patients were randomly assigned (1:1) to receive tezepelumab 420 mg or placebo subcutaneously every 4 weeks for up to 52 weeks. Randomisation was stratified by geographical region and by number of exacerbations in the 12 months before enrolment. Participants, investigators, site staff, and the study sponsor were masked to treatment assignment. The primary endpoint was the annualised rate of moderate or severe COPD exacerbations over 52 weeks. A prespecified subgroup analysis assessed the primary endpoint in patients grouped by baseline blood eosinophil counts (BECs). Efficacy and safety were assessed in all patients who received at least one dose of study drug. This trial is registered with <span><span>ClinicalTrials.gov</span><svg aria-label="Opens in new window" focusable="false" height="20" viewbox="0 0 8 8"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span>, <span><span>NCT04039113</span><svg aria-label="Opens in new window" focusable="false" height="20" viewbox="0 0 8 8"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span> (completed).<h3>Findings</h3>Between July 30, 2019, and Oct 4, 2022, 333 patients (mean age 67·2 years [SD 7·0]; 145 [44%] female and 188 [56%] male; 293 [88%] White, 34 [10%] Asian, and four [1%] Black or African American) were randomly assigned and treated with tezepelumab (n=165) or placebo (n=168). The annualised rate of moderate or severe COPD exacerbations over 52 weeks was 1·75 for tezepelumab versus 2·11 for placebo (rate ratio 0·83 [90% CI 0·64–1·06]; p=0·10 [one-sided]; the primary endpoint was not met). In prespecified subgroup analyses, the annualised rate of moderate or severe COPD exacerbations over 52 weeks was 2·04 with tezepelumab versus 1·71 with placebo (rate ratio 1·19 [95% CI 0·75–1·90]) in patients with a baseline BEC of less than 150 cells per μL, 1·64 versus 2·47 (0·66 [0·42–1·04]) in patients with a baseline BEC of 150 cells per μL to less than 300 cells per μL, and 1·20 versus 2·24 (0·54 [0·25–1·15]) in patients with a baseline BEC of 300 cells per μL or higher. Adverse events occurred in 133 (81%)
tezepelumab是一种人单克隆抗体,可阻断胸腺基质淋巴生成素,慢性阻塞性肺疾病(COPD)患者中与健康个体相比,其表达增加。我们的目的是评估tezepelumab在接受三次吸入治疗的中度至极重度COPD患者中的疗效和安全性。方法course是一项双盲、随机、安慰剂对照的2a期临床试验,横跨亚洲、欧洲和北美10个国家的90个试验点。符合条件的参与者年龄在40-80岁之间,有中度至非常严重的气流限制,正在接受三次吸入维持治疗,并且在入组前的12个月内至少有两次中度至重度COPD恶化。患者被随机分配(1:1)接受tezepelumab 420 mg或安慰剂皮下注射,每4周持续52周。随机化按地理区域和入组前12个月的恶化次数分层。参与者、调查人员、现场工作人员和研究发起者被掩盖到治疗分配。主要终点是52周内中度或重度COPD恶化的年化率。预先指定的亚组分析评估了基线血嗜酸性粒细胞计数(BECs)分组患者的主要终点。对所有接受至少一剂研究药物的患者的疗效和安全性进行了评估。该试验已在ClinicalTrials.gov注册,编号NCT04039113(已完成)。在2019年7月30日至2022年10月4日期间,333例患者(平均年龄67.2岁[SD 7.0];女性145人(44%),男性188人(56%);293例(88%)白人,34例(10%)亚洲人,4例(1%)黑人或非裔美国人,随机分配并接受tezepelumab (n=165)或安慰剂(n=168)治疗。在52周内,tezepelumab组中度或重度COPD恶化的年化率为1.75,安慰剂组为2.11(比率比0.83 [90% CI 0.64 - 1.06];p = 0·10(单边);主要终点未达到)。在指定子群分析,中度或重度慢性阻塞性肺病急性加重的年增长率在52周2·04 tezepelumab和1·71与安慰剂(率比1·19[95%可信区间0·75 - 1·90])患者的基线BEC少于150细胞/μL, 1·64和2·47(0·66(0·42-1·04))患者的基线BEC的150个细胞/μL少于300细胞/μL, 1 * 20和2 * 24(0·54[0·赔率·15])患者的基线BEC的300细胞/μL或更高。tezepelumab组165例患者中有133例(81%)发生不良事件,安慰剂组168例患者中有126例(75%)发生不良事件。tezepelumab组49例(30%)患者和安慰剂组50例(30%)患者发生严重不良事件。5例患者在接受研究治疗期间死亡:2例在tezepelumab组,3例在安慰剂组。研究者评估没有确定死亡与研究治疗有因果关系。解释:与安慰剂相比,tezepelumab未观察到中度或重度COPD恶化的年化率显著降低。需要进一步的研究来评估tezepelumab对中度至极重度COPD患者的疗效,特别是基线BEC为150细胞/ μL或更高的患者。Tezepelumab耐受性良好,无安全性问题。资助阿斯利康和安进。
{"title":"Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial","authors":"Dave Singh, Christopher E Brightling, Klaus F Rabe, MeiLan K Han, Stephanie A Christenson, M Bradley Drummond, Alberto Papi, Ian D Pavord, Nestor A Molfino, Gun Almqvist, Ales Kotalik, Åsa Hellqvist, Monika Gołąbek, Navreet S Sindhwani, Sandhia S Ponnarambil","doi":"10.1016/s2213-2600(24)00324-2","DOIUrl":"https://doi.org/10.1016/s2213-2600(24)00324-2","url":null,"abstract":"&lt;h3&gt;Background&lt;/h3&gt;Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, which has shown increased expression in patients with chronic obstructive pulmonary disease (COPD) compared with healthy individuals. We aimed to assess the efficacy and safety of tezepelumab in patients with moderate to very severe COPD despite receiving triple inhaled therapy.&lt;h3&gt;Methods&lt;/h3&gt;COURSE was a double-blind, randomised, placebo-controlled, phase 2a trial across 90 sites in ten countries in Asia, Europe, and North America. Eligible participants were aged 40–80 years, had moderate to very severe airflow limitation, were receiving triple inhaled maintenance therapy, and had at least two moderate to severe COPD exacerbations in the 12 months before enrolment. Patients were randomly assigned (1:1) to receive tezepelumab 420 mg or placebo subcutaneously every 4 weeks for up to 52 weeks. Randomisation was stratified by geographical region and by number of exacerbations in the 12 months before enrolment. Participants, investigators, site staff, and the study sponsor were masked to treatment assignment. The primary endpoint was the annualised rate of moderate or severe COPD exacerbations over 52 weeks. A prespecified subgroup analysis assessed the primary endpoint in patients grouped by baseline blood eosinophil counts (BECs). Efficacy and safety were assessed in all patients who received at least one dose of study drug. This trial is registered with &lt;span&gt;&lt;span&gt;ClinicalTrials.gov&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;, &lt;span&gt;&lt;span&gt;NCT04039113&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt; (completed).&lt;h3&gt;Findings&lt;/h3&gt;Between July 30, 2019, and Oct 4, 2022, 333 patients (mean age 67·2 years [SD 7·0]; 145 [44%] female and 188 [56%] male; 293 [88%] White, 34 [10%] Asian, and four [1%] Black or African American) were randomly assigned and treated with tezepelumab (n=165) or placebo (n=168). The annualised rate of moderate or severe COPD exacerbations over 52 weeks was 1·75 for tezepelumab versus 2·11 for placebo (rate ratio 0·83 [90% CI 0·64–1·06]; p=0·10 [one-sided]; the primary endpoint was not met). In prespecified subgroup analyses, the annualised rate of moderate or severe COPD exacerbations over 52 weeks was 2·04 with tezepelumab versus 1·71 with placebo (rate ratio 1·19 [95% CI 0·75–1·90]) in patients with a baseline BEC of less than 150 cells per μL, 1·64 versus 2·47 (0·66 [0·42–1·04]) in patients with a baseline BEC of 150 cells per μL to less than 300 cells per μL, and 1·20 versus 2·24 (0·54 [0·25–1·15]) in patients with a baseline BEC of 300 cells per μL or higher. Adverse events occurred in 133 (81%) ","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"62 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142788571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A career development programme for women at an academic medical centre 一个学术医疗中心的妇女职业发展方案
IF 76.2 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2024-12-05 DOI: 10.1016/s2213-2600(24)00379-5
Marika Orlov, Sarah L Rhoads, Kelsey Hills-Dunlap, Sunita Sharma, Sarah Jolley
No Abstract
没有抽象的
{"title":"A career development programme for women at an academic medical centre","authors":"Marika Orlov, Sarah L Rhoads, Kelsey Hills-Dunlap, Sunita Sharma, Sarah Jolley","doi":"10.1016/s2213-2600(24)00379-5","DOIUrl":"https://doi.org/10.1016/s2213-2600(24)00379-5","url":null,"abstract":"No Abstract","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"27 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142782376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GOLD COPD report: 2025 update GOLD COPD报告:2025年更新
IF 76.2 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2024-12-05 DOI: 10.1016/s2213-2600(24)00413-2
Priya Venkatesan
No Abstract
没有抽象的
{"title":"GOLD COPD report: 2025 update","authors":"Priya Venkatesan","doi":"10.1016/s2213-2600(24)00413-2","DOIUrl":"https://doi.org/10.1016/s2213-2600(24)00413-2","url":null,"abstract":"No Abstract","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"26 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142782706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Augmenting clinical trials in asthma through digital technology, decentralised designs, and person-centric endpoints: opportunities and challenges 通过数字技术、分散设计和以人为中心的终点来扩大哮喘临床试验:机遇与挑战
IF 76.2 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2024-12-05 DOI: 10.1016/s2213-2600(24)00327-8
Job F M van Boven, Richard W Costello, Kit C B Roes, Guy G Brusselle, Kjeld Hansen, Jerry A Krishnan, Christopher E Brightling, Nicolas Roche, Salman Siddiqui, Bruce J Kirenga, Hilary Pinnock, Amy H Y Chan
Digital technologies (eg, smart inhalers, wearables, and sensors) allow for remote, objective, granular, and non-invasive data collection, making them attractive for research evaluating interventions in airways diseases with variable trajectories, such as asthma. Such technologies offer the opportunity to move towards decentralised clinical trials that are done partly or fully outside the classic clinical trial setting and are characterised by remote data collection and monitoring. This approach to evaluating clinical, pharmacological, or behavioural interventions could facilitate recruitment of inclusive and generalisable study populations, enhance personalisation and sustainability, reduce research costs, and accelerate the timeline to novel asthma treatments' market access. This Personal View discusses the application of digital technologies and endpoints within trials; the concept of hybrid and decentralised designs; describes a fully decentralised trial in asthma; and explores the strengths, weaknesses, opportunities, and threats regarding their implementation from the clinician, patient expert, low-resource, and regulator viewpoints.
数字技术(如智能吸入器、可穿戴设备和传感器)允许远程、客观、颗粒和非侵入性数据收集,使其对评估具有可变轨迹的气道疾病(如哮喘)干预措施的研究具有吸引力。这些技术提供了向分散临床试验方向发展的机会,这些临床试验部分或完全在传统临床试验环境之外进行,其特点是远程数据收集和监测。这种评估临床、药理学或行为干预措施的方法可以促进招募包容性和可推广的研究人群,增强个性化和可持续性,降低研究成本,并加快新型哮喘治疗药物的市场准入。本个人观点讨论了数字技术和终端在试验中的应用;混合和分散设计的概念;描述了一项完全分散的哮喘试验;并从临床医生、患者专家、低资源和监管机构的角度探讨其实施的优势、劣势、机会和威胁。
{"title":"Augmenting clinical trials in asthma through digital technology, decentralised designs, and person-centric endpoints: opportunities and challenges","authors":"Job F M van Boven, Richard W Costello, Kit C B Roes, Guy G Brusselle, Kjeld Hansen, Jerry A Krishnan, Christopher E Brightling, Nicolas Roche, Salman Siddiqui, Bruce J Kirenga, Hilary Pinnock, Amy H Y Chan","doi":"10.1016/s2213-2600(24)00327-8","DOIUrl":"https://doi.org/10.1016/s2213-2600(24)00327-8","url":null,"abstract":"Digital technologies (eg, smart inhalers, wearables, and sensors) allow for remote, objective, granular, and non-invasive data collection, making them attractive for research evaluating interventions in airways diseases with variable trajectories, such as asthma. Such technologies offer the opportunity to move towards decentralised clinical trials that are done partly or fully outside the classic clinical trial setting and are characterised by remote data collection and monitoring. This approach to evaluating clinical, pharmacological, or behavioural interventions could facilitate recruitment of inclusive and generalisable study populations, enhance personalisation and sustainability, reduce research costs, and accelerate the timeline to novel asthma treatments' market access. This Personal View discusses the application of digital technologies and endpoints within trials; the concept of hybrid and decentralised designs; describes a fully decentralised trial in asthma; and explores the strengths, weaknesses, opportunities, and threats regarding their implementation from the clinician, patient expert, low-resource, and regulator viewpoints.","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"13 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142782707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Time to escalate quality assurance in small-cell lung cancer radiotherapy trials 是时候提高小细胞肺癌放疗试验的质量保证了
IF 76.2 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2024-12-03 DOI: 10.1016/s2213-2600(24)00338-2
Gerard M Walls, Marcel van Herk, Corinne Faivre-Finn
No Abstract
没有抽象的
{"title":"Time to escalate quality assurance in small-cell lung cancer radiotherapy trials","authors":"Gerard M Walls, Marcel van Herk, Corinne Faivre-Finn","doi":"10.1016/s2213-2600(24)00338-2","DOIUrl":"https://doi.org/10.1016/s2213-2600(24)00338-2","url":null,"abstract":"No Abstract","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"29 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142763193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Time to escalate quality assurance in small-cell lung cancer radiotherapy trials – Authors' reply 是时候提高小细胞肺癌放疗试验的质量保证了——作者的答复
IF 76.2 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2024-12-03 DOI: 10.1016/s2213-2600(24)00335-7
Jiayi Yu, Jun Zhao, Anhui Shi
No Abstract
没有抽象的
{"title":"Time to escalate quality assurance in small-cell lung cancer radiotherapy trials – Authors' reply","authors":"Jiayi Yu, Jun Zhao, Anhui Shi","doi":"10.1016/s2213-2600(24)00335-7","DOIUrl":"https://doi.org/10.1016/s2213-2600(24)00335-7","url":null,"abstract":"No Abstract","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"12 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142763194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Lancet Respiratory Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1